Lenograstim: Difference between revisions
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
Kiran Singh (talk | contribs) No edit summary |
||
| Line 24: | Line 24: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__Notoc__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Lenograstim''' is a [[recombinant]] [[granulocyte colony-stimulating factor]] which functions as a [[immunostimulator]].<ref name="pmid15761020">{{cite journal |author=Amadori S, Suciu S, Jehn U, ''et al'' |title=Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study |journal=Blood |volume=106 |issue=1 |pages=27–34 |year=2005 |pmid=15761020 |doi=10.1182/blood-2004-09-3728}}</ref> | '''Lenograstim''' is a [[recombinant]] [[granulocyte colony-stimulating factor]] which functions as a [[immunostimulator]].<ref name="pmid15761020">{{cite journal |author=Amadori S, Suciu S, Jehn U, ''et al'' |title=Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study |journal=Blood |volume=106 |issue=1 |pages=27–34 |year=2005 |pmid=15761020 |doi=10.1182/blood-2004-09-3728}}</ref> | ||
| Line 29: | Line 33: | ||
{{reflist|2}} | {{reflist|2}} | ||
{{Immunostimulants}} | {{Immunostimulants}} | ||
{{pharma-stub}} | {{pharma-stub}} | ||
Latest revision as of 17:18, 13 April 2015
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Lenograstim |
|
Articles |
|---|
|
Most recent articles on Lenograstim Most cited articles on Lenograstim |
|
Media |
|
Powerpoint slides on Lenograstim |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lenograstim at Clinical Trials.gov Clinical Trials on Lenograstim at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lenograstim
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lenograstim Discussion groups on Lenograstim Patient Handouts on Lenograstim Directions to Hospitals Treating Lenograstim Risk calculators and risk factors for Lenograstim
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lenograstim |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as a immunostimulator.[1]
References
- ↑ Amadori S, Suciu S, Jehn U; et al. (2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood. 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMID 15761020.
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes